Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$25.8 million.

  • Century Therapeutics' Free Cash Flow rose 901.1% to -$25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.0 million, marking a year-over-year increase of 80.49%. This contributed to the annual value of -$110.3 million for FY2024, which is 803.75% down from last year.
  • Century Therapeutics' Free Cash Flow amounted to -$25.8 million in Q3 2025, which was up 901.1% from -$27.9 million recorded in Q2 2025.
  • Century Therapeutics' Free Cash Flow's 5-year high stood at $82.7 million during Q1 2022, with a 5-year trough of -$36.0 million in Q2 2022.
  • In the last 4 years, Century Therapeutics' Free Cash Flow had a median value of -$27.9 million in 2025 and averaged -$21.2 million.
  • Examining YoY changes over the last 5 years, Century Therapeutics' Free Cash Flow showed a top increase of 5032.6% in 2023 and a maximum decrease of 14137.34% in 2023.
  • Over the past 4 years, Century Therapeutics' Free Cash Flow (Quarter) stood at -$29.2 million in 2022, then rose by 6.74% to -$27.2 million in 2023, then rose by 10.98% to -$24.2 million in 2024, then fell by 6.42% to -$25.8 million in 2025.
  • Its Free Cash Flow was -$25.8 million in Q3 2025, compared to -$27.9 million in Q2 2025 and -$35.1 million in Q1 2025.